Colforsin (Forskolin, HL 362)

For research use only. Not for use in humans.

製品コードS2449 別名:Coleonol, Colforsin

Colforsin (Forskolin, HL 362)化学構造

CAS No. 66575-29-9

Colforsin (Forskolin, HL 362, Coleonol, Colforsin) is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology. Forskolin also activates PXR and FXR activity. Forskolin stimulates autophagy.

サイズ 価格(税別)  
JPY 20200
JPY 46800
JPY 63400
JPY 96600
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(100)

製品安全説明書

cAMP阻害剤の選択性比較

生物活性

製品説明 Colforsin (Forskolin, HL 362, Coleonol, Colforsin) is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology. Forskolin also activates PXR and FXR activity. Forskolin stimulates autophagy.
ターゲット
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
体外試験

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (Gs)–AC complexes. Activation of s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of s-Forskolin potentiation of AC activity. [1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29  M33nO2Fxd3C2b4Ppd{BCe3OjeR?= MUG0NOKh|ryP NGXrUXo1QMLiaB?= M1TETGROW09? MVvpcoR2[2W|IHPoZY5o\XNiaX6geIhmKHCqb4PwbI9zgWyjdHnvckB{fGG2dYOgc4YhWFB{QTD0ZZJo\XS| M3m4dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm3OFUyLz5{NEm5O|Q2OTxxYU6=
SW480 M2rRdGFxd3C2b4Ppd{BCe3OjeR?= NYrx[pdwPDEEoN88US=> NH;NZ3o1QMLiaB?= MUTEUXNQ M3OxWolv\HWlZYOgZ4hidmenczDpckB1cGVicHjvd5Bpd3K7bHH0bY9vKHO2YYT1d{Bw\iCSUELBJJRiemendIO= MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
HT-29  M1fXemFxd3C2b4Ppd{BCe3OjeR?= NH7EOXo1OMLizszN M17HTVQ5yqCq MlLrSG1UVw>? NYrmeYRicW6mdXPld{BidiCjY4TpeoF1cW:wIH;mJINie3Cjc3WgN{84 Mkn0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480 MYLBdI9xfG:|aYOgRZN{[Xl? NWTUc|M6PDEEoN88US=> NET3Z5Q1QMLiaB?= NVzPNJRFTE2VTx?= MY\pcoR2[2W|IHHuJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|L{e= MlrPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
HT-29  NEP3THVHfW6ldHnvckBCe3OjeR?= NX[2ZoREPDEEoN88US=> MoCwO{Bl NHXNeWJFVVOR NX;2e5l6emWmdXPld{Bkd2yxbn;zdIhmemViZn;ycYF1cW:wIHPhdIFjcWyrdIpCpC=> MoXwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480 MmfwSpVv[3Srb36gRZN{[Xl? NYjwcoxGPDEEoN88US=> MXS3JIQ> MmHGSG1UVw>? NEjGT5pz\WS3Y3XzJINwdG:wb4PwbIVz\SCob4LtZZRqd25iY3HwZYJqdGm2edMg MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
HT-29  NUf6VVRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYS5NotwPDEEoN88US=> NFnPT5cxNTd{IHi= NEj2W25FVVOR NUPRb5I2cW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? NF3DblE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O|Q2OSd-MkS5PVc1PTF:L3G+
SW480 NXTUUIp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7kXJg1OMLizszN NE\vZY0xNTd{IHi= NIX3[HdFVVOR MV\pcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 NFjWVXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O|Q2OSd-MkS5PVc1PTF:L3G+
HT-29  NXLtcG5ZTnWwY4Tpc44hSXO|YYm= MYG0NOKh|ryP NFzjd4c1QMLiaB?= NFzxOlZFVVOR M1v5OIFkfGm4YYTld{BRWDKD MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
SW480 NXfxUmtVTnWwY4Tpc44hSXO|YYm= NVTNfnh4PDEEoN88US=> NEfSSIM1QMLiaB?= MmDzSG1UVw>? NWfCUWRR[WO2aY\heIV{KFCSMlG= NFXHdIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O|Q2OSd-MkS5PVc1PTF:L3G+
C6 MlTVSpVv[3Srb36gRZN{[Xl? MoXWNVAh|ryPwrC= MnvTNlAhdWmw MmDlbY5kemWjc3XzJINCVVBiYXPjeY12dGG2aX;u NYnTXY54RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlk1OTdpPkK1NFY6PDF5PD;hQi=>
Huh-7 MX;GeY5kfGmxbjDBd5NigQ>? NGe5b3AxNTJyIN88US=> Mlf5NkBpyqB? M3fSfpJme3WudIOgbY4h[SCmb4PlMYRmeGWwZHXueEBqdmO{ZXHz[UBqdiClLV35Z{BmgHC{ZYPzbY9vKGG2IITo[UBxem:2ZXnuJIFv\CCvUl7BJIxmfmWucx?= NFT4S3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwPVg{PCd-MkWxNFk5OzR:L3G+
THP-1  MlXGSpVv[3Srb36gRZN{[Xl? Mki0NU8yOCEQvF2= NGXZOpAzyqCq MonwSG1UV8Li Mk\Id5VxeHKnc4Pld{BOS1BvMTDwdo9lfWO2aX;uxsA> NVi0RVJLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVQ5QDJpPkK1NVU1QDh{PD;hQi=>
BeWo  MWTGeY5kfGmxbjDBd5NigQ>? M360[FIxKML3TR?= MnPlOFghcA>? MUPEUXNQyqB? MVfpcoR2[2W|IHPlcIwh\nW|aX;u NEnvV5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG4OFQ4Pyd-MkWxPFQ1Pzd:L3G+
ventricular cardiomyocytes  NVL4fGtZTnWwY4Tpc44hSXO|YYm= NEDoUWUxNjBzLUGwJO69VQ>? NGT1cYhmfm:tZYOgZY4hcW6xdILvdIlkKHKnc4DvcpNmKDF{MNMxNVUmKGGkb4\lJIJie2GuIIfpeIgh[W5iRVO1NOKhd2ZiMj6yJOK2VQ>? NV7lbG9zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNFMyOTNpPkK1NlA{OTF|PD;hQi=>
ventricular cardiomyocytes  MX\GeY5kfGmxbjDBd5NigQ>? NEPOVJQxNjBzLUGwJO69VQ>? NXXke5lNcW6lcnXhd4V{KCClQV3QJIFk[3WvdXzheIlwdg>? NU\Ne44zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNFMyOTNpPkK1NlA{OTF|PD;hQi=>
MIN6  MYrGeY5kfGmxbjDBd5NigQ>? M1XFTlExKM7:TdMg MWmzJIg> M3jiWIlv[3KnYYPld{BFOyCvUl7BJIV5eHKnc4Ppc44> M3jDZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkSxNVI1Lz5{NUK0NVEzPDxxYU6=
L6 M1HWZWZ2dmO2aX;uJGF{e2G7 M2rBcVQxKML3TR?= NF;5TYQzPCCq NX3YcItRcW6qaXLpeJMhTE2KMT3pcoR2[2WmIFHreEBi[3SrdnH0bY9v MkXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NEe1OVAoRjJ3MkS3OVUxRC:jPh?=
HEK‐CFTR NH;HSYFHfW6ldHnvckBCe3OjeR?= NWntVo1sOuLCk{WwxsDPxE1? MUGwMVEzKG2rbh?= MojVSG1UV8Li MWDpcoR2[2W|IHGg[I9{\eLCkHTldIVv\GWwdDDpc4Rq\GViZX\mcJV5yqB? NUTNeoZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlMzODdpPkK1NlY{OjB5PD;hQi=>
SK-N-SH NHnSZllE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{PRclExKM7:TdMg M1TIeVQ5KGh? NYrOdVB2\W6qYX7j[ZMhW0tvTj3TTEBv\XW{b3LsZZN1d22jIHPlcIwhfmmjYnnsbZR6 M2rIV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[2NFY{Lz5{NUK2OlA3OzxxYU6=
SK-N-AS  NHy4OmZHfW6ldHnvckBCe3OjeR?= MX:xNEDPxE4EoB?= M2ruRVExNzNyL{[wJI1qdg>? NYHQNFB2cW6lcnXhd4V{KGyndnXsd{Bw\iCyLd8yMYNifGWwaX6gLJNmejZ5NTmgZY5lKGmwZIXj[ZMh[WOldX31cIF1cW:wIH;mJJAu|rJvY3H0[Y5qdiBqc3XyOlc2MSCrbjCodIVzcSmwdXPs[YFzKHKnZ3nvcpM> Mn20QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{Nk[wOlMoRjJ3Mk[2NFY{RC:jPh?=
SK-N-AS  Moj2SpVv[3Srb36gRZN{[Xl? MY[xNEDPxE4EoB?= NVT5fHJkOzBibXnu NFrMd4hqdmS3Y3XzJJBpd3OyaH;yfYxifGmxbjDv[kDPui2lYYTlcolvKCi|ZYK2O|UqNCCyLVfTT|PPuiBqc3XyPUkh[W6mIHPvcoNwdWm2YX70JIhq\2incjDs[ZZmdHNib3[gZYN1cX[nLDD1cpBpd3OyaH;yfYxifGWmLDFOtk1k[XSnbnnu MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4NkC2N{c,OjV{Nk[wOlM9N2F-
SK-N-AS  MnSySpVv[3Srb36gRZN{[Xl? MVexNEDPxE4EoB?= MorlNlQhcA>? NUW1[4l2cW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGO7Y3zpckBFOQ>? MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4NkC2N{c,OjV{Nk[wOlM9N2F-
SK-N-AS  MX3GeY5kfGmxbjDBd5NigQ>? M1XndlExKM7:TdMg M33KTVI1KGh? NX7zb|lXcW6lcnXhd4V{KHSqZTDjRW1RKGyndnXsd:Kh MnrVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{Nk[wOlMoRjJ3Mk[2NFY{RC:jPh?=
SK-N-AS  MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MniyNVAh|ryPwrC= NHnEeHEzPC92ODDo M3\BRoVvcGGwY3XzJJRqdWVvZHXw[Y5l\W62bImgZ4VtdHWuYYKgeoli[mmuaYT5xsA> NVTRdlhLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlYxPjNpPkK1NlY3ODZ|PD;hQi=>
granulosa cells MkixSpVv[3Srb36gRZN{[Xl? MUKxNEDPxE1? MkfENlQhcA>? M2fETolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIGLHV|IheHKxbX;0[ZIh[WO2aY\peJk> NV:2Umw4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN|kyODVpPkK1N|M6OTB3PD;hQi=>
granulosa cells MYjGeY5kfGmxbjDBd5NigQ>? NF\nXHIyOCEQvF2= MoDXNlQhcA>? M4TNcolv[3KnYYPld{B1cGViaX70[Y5{cXS7IH;mJGRPSS:ycn;0[YlvKGOxbYDs[Zg> NGS0T5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzPVExPSd-MkWzN|kyODV:L3G+
granulosa cells MVHGeY5kfGmxbjDBd5NigQ>? M4TqOFExKM7:TR?= M3rmcFEzNzJ2IHi= NIqyNG9qdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDy[ZBwenSncjDhZ5Rqfmm2eTDmc5IhfGinIHzvcodme3RiZoLh[41mdnRiKPMIllg2PC9tMUjSS3MzNkyXQzm= MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN|OUGwOUc,OjV|M{mxNFU9N2F-
granulosa cells M4XGVWZ2dmO2aX;uJGF{e2G7 MnjkNVAh|ryP NFXPR2QyOi9{NDDo MnLjbY5kemWjc3XzJJRp\SCuZY\lcJMhd2cEoGLHV|LDqG2UTlG= M4jzWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O5NVA2Lz5{NUOzPVExPTxxYU6=
BeWo  NYj4THZ2TnWwY4Tpc44hSXO|YYm= NX7SUItxOjEEoNM1US=> M4DZU|Q5yqCqwrC= MkHhSG1UV8Li MWTkc5dvemWpdXzheIV{KHSqZTDs[ZZmdCCxZjDHR20uOQ>? M2P5elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{[yNlYxLz5{NUO2NlI3ODxxYU6=
BeWo  NHyxNIZHfW6ldHnvckBCe3OjeR?= MXOyNOKhyrWP M2ToWFQ5yqCqwrC= NWfzV5hCTE2VT9Mg NXq2V2o4\G:5boLl[5Vt[XSnczD0bIUhdGW4ZXygc4YhXE2HTV[xOi=> M2njPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{[yNlYxLz5{NUO2NlI3ODxxYU6=
BeWo  NW\FRm1{TnWwY4Tpc44hSXO|YYm= NUfMNFc6OjEEoNM1US=> NIK3XXk1QMLiaNMg MoDxSG1UV8Li MVLpcoNz\WG|ZYOgeIhmKGKndHGtbGNIKHKnbHXhd4U> MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN4MkK2NEc,OjV|NkKyOlA9N2F-
EM1  MmDzSpVv[3Srb36gRZN{[Xl? NGrKTYcyPeLCit88US=> MVu0PEBp MXry[YR2[2W|IITo[UBmgHC{ZYPzbY9vKG:owrDMTWbDqG:{wrDQWGdUOsLiaX9CpGNCVFJvIH;yxsBGWEGFMj3zbYxmdmOnZDDFUVEh[2WubIRCpC=> M{fSTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{e4OlYyLz5{NUO3PFY3OTxxYU6=
Primary bovine chondrocytes MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX21{txO MnHqOFghcA>? M1LRVJJmfmW{c3XzJJRp\SCrbnjpZol1d3K7IHXm[oVkfCCxZjDj[Yxm[2:6aXKgc44heHKxbHnm[ZJifGmxbjDpckBoem:5dHigdIxifGViY3jvcoRzd2O7dHXz NVnMXmZRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NFYxOTZpPkK1OFA3ODF4PD;hQi=>
RBMECs M{TOVGZ2dmO2aX;uJGF{e2G7 MoPhOeKh|ryP MlKwNUBp MVvicI9kc3NidHjlJIFkfGmwIHP5eI9{c2WuZYTvckBz\WG{cnHu[4Vu\W62IIPl[Y4hf2m2aDDFUWFRNUmLIITy[YF1dWWwdNMg MmjsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MU[2OVEoRjJ3NEG2OlUyRC:jPh?=
RBMECs Mli2SpVv[3Srb36gRZN{[Xl? NFXzOlA2yqEQvF2= M3fvXFEhcA>? MXficI9kc3NidHjlJGVOSVBvSVmtbY5lfWOnZDDjbIFv\2ViaX6gUWxEKHCqb4PwbI9zgWyjdHnvci=> M1j4elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEG2OlUyLz5{NUSxOlY2OTxxYU6=
RBMECs M323cGZ2dmO2aX;uJGF{e2G7 MXS1xsDPxE1? MXSxJIg> M{HlfpJmfmW{c3XzJJRp\SClaHHu[4V{KGmwIGrPMVEh\Gm|dILpZpV1cW:wIIPl[Y4hf2m2aDDFUWFRNUmLIITy[YF1dWWwdB?= M17YT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEG2OlUyLz5{NUSxOlY2OTxxYU6=
RBMECs MlzNSpVv[3Srb36gRZN{[Xl? MnvwOeKh|ryP MYCxJIg> M1ywVIlvcGmkaYTzJJRp\SCmZXPy[YF{\WRib3[gZY1wfW62IH;mJHpQNTFiaX6gUWZ{KGmwZIXj[YQh[nliRV3BVE1KUQ>? MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzNk[1NUc,OjV2MU[2OVE9N2F-
RBMECs NVPmXmhwTnWwY4Tpc44hSXO|YYm= NYHwVWRDPcLizszN MnT4NUBp MV\wdoV3\W62czD0bIUhcW6lcnXhd4UhcW5iSGLQJIZtfXhiYXPyc5N{KHSqZTDCWGIhcW6mdXPl[EBjgSBiRV3BVE1KUQ>? NX3L[3RLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVY3PTFpPkK1OFE3PjVzPD;hQi=>
RBMECs NHfRcYJHfW6ldHnvckBCe3OjeR?= MUW1xsDPxE1? NY\4[JBJOSCq NWraSZV7eHKndnXueJMhfGinIFXNRXAuUUlvaX7keYNm\CCWRVXSJJZidHWnIHTlZ5Jm[XOn MmPUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MU[2OVEoRjJ3NEG2OlUyRC:jPh?=
RBMECs M3PlRmZ2dmO2aX;uJGF{e2G7 M124clXDqM7:TR?= M2Oyd|EhcA>? M3PNVYJtd2OtczD0bIUh[WO2aY\heIlwdiCxZjDSbI9CN1KRQ1ugbY5lfWOnZDDifUBGVUGSLVnJ NWLJOlJkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVY3PTFpPkK1OFE3PjVzPD;hQi=>
RBMECs NXnGUoN{TnWwY4Tpc44hSXO|YYm= NYTQXFRkOC5yNT:wMlUwPSEQvF2= M1jUWFAvOjViaB?= M2XyN4lv[3KnYYPld{BkSU2SIHPvcoNmdnS{YYTpc44> NVPSN4hvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVY3PTFpPkK1OFE3PjVzPD;hQi=>
ThGCs  M2qwNGZ2dmO2aX;uJGF{e2G7 Ml7nNVDjiIsQvF2= MWGzJIg> NFzPW41qdmirYnn0d{B1cGViZX\m[YN1KG:oIFiyU|Ihd25iRVTONkBuWk6D NHLKWVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzN|AzPyd-MkW0N|MxOjd:L3G+
ThGCs  NUTzSopuTnWwY4Tpc44hSXO|YYm= NXfDRpR3OTEkgJtOwG0> M1vZWlTjiIqq NGDUT3RqdmO{ZXHz[ZMhS2:FbEKtbY5lfWOnZDDFSG4zyqCpZX7lJIV5eHKnc4Ppc44> NYHvXotwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N|MxOjdpPkK1OFM{ODJ5PD;hQi=>
ThGCs  M3u3c2Z2dmO2aX;uJGF{e2G7 M2nK[FEx6oDMzszN NYD1VnJQPOLCini= MnHlZZVodWWwdIOgTGlHOUFibHX2[Yx{KHSqYYSge4Vz\SC|dHnteYxifGWmIHL5JGNwS2x{ MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR|M{CyO{c,OjV2M{OwNlc9N2F-
LNCaP  NHzGS5pHfW6ldHnvckBCe3OjeR?= NVHWPIZkOTEEoN88US=> Ml:xNVIhcMLi M1HyNGROW09? MYjpcoR2[2W|IHGg[JJidWG2aXOgbY5kemWjc3Wgc4YhS1KHQkGgZYN1cX[rdIm= Mn3uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NEiwPVkoRjJ3NUS4NFk6RC:jPh?=
BeWo NUfTRnFVTnWwY4Tpc44hSXO|YYm= M1zZS|IxyqEEtV2= NH3aNGY1QMLiaB?= M2XrcmROW09? NGDPfIlqdmO{ZXHz[ZMhfGinIHHkbIV{cW:wIH;mJHRJWC1zIH3vco9kgXSncx?= NIrVemI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW2Olc1OCd-MkW1OlY4PDB:L3G+
BeWo M{DaV2Z2dmO2aX;uJGF{e2G7 M4fWVVIxyqEEtV2= M{DGUlQ5yqCq NYTQeFdSTE2VTx?= MYjpcoNz\WG|ZYOgeIhmKGSrZn\ldoVvfGmjdHnvckBw\iCEZWfvJINmdGy| NWHOV5BRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlY4PDBpPkK1OVY3PzRyPD;hQi=>
OCI-Ly18  MX;GeY5kfGmxbjDBd5NigQ>? NUTDfpplPDEEoN88US=> MW[xxsBpyqB? NHjNe3JFVVOR NF7rUZNqdmS3Y3XzJJRp\SCrbnPy[Y1mdnRib3[gZ2FOWCClb37j[Y51emG2aX;udy=> M{XpSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUe2NlIxLz5{NUW3OlIzODxxYU6=
OCI-Ly1  M{juUWZ2dmO2aX;uJGF{e2G7 MWG0NOKh|ryP Mn;RNeKhcMLi MoHPSG1UVw>? MnvObY5lfWOnczD0bIUhcW6lcnXt[Y51KG:oIHPBUXAh[2:wY3XueJJifGmxboO= MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV5NkKyNEc,OjV3N{[yNlA9N2F-
3T3-L1 MY\GeY5kfGmxbjDBd5NigQ>? NEfyc20zNjVxNTFOwG0> MlSwNlQhcMLi Mn7Ld4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiQWTHUEBxem:2ZXnuJIV5eHKnc4Ppc44h[XRiYXzsJIRwe2W|IITld5Rm\A>? M4rXWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUmwOVk4Lz5{NUW5NFU6PzxxYU6=
HEK293  MmDKSpVv[3Srb36gRZN{[Xl? NIHM[XU26oDLwsXN NEjHfXc{OCCvaX6= M1v2OIlv[3KnYYPld{BkSU2SIHzleoVtew>? NGS5[VY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW5NVkxQCd-MkW1PVE6ODh:L3G+
hADSCs Ml7WSpVv[3Srb36gRZN{[Xl? MVi15qCKyrWP M3;vNFMxKG2rbh?= MX;pcoNz\WG|ZYOgZ2FOWCCuZY\lcJM> NYf3eIlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVE6ODhpPkK1OVkyQTB6PD;hQi=>
SH-SY5Y  Ml[xSpVv[3Srb36gRZN{[Xl? NVnpWWlWOTEEoN88US=> M1vuTFHDqGkEoB?= NULlWmVzcW6lcnXhd4V{KEGJQ{GgcXJPSSCuZY\lcC=> NH7q[GU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW5O|Q{Oyd-MkW1PVc1OzN:L3G+
SH-SY5Y  NYrHVXlqTnWwY4Tpc44hSXO|YYm= M{P4dlExyqEQvF2= NF3ubY4yyqCqwrC= NUHNSnR2cW6lcnXhd4V{KEyXQzDhZ5Rqfmm2eR?= MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7N{SzN{c,OjV3OUe0N|M9N2F-
UACC-647  Ml\wSpVv[3Srb36gRZN{[Xl? NGjrUFIyOMLizszN NFL5W4MyPSCvaX6= NFXuR3pFVVOR M{nBbolv[3KnYYPld{BmTUZ{IIDoc5NxcG:{eXzheIlwdiCuZY\lcJPDqA>? M4nFXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{CzNFI2Lz5{NUewN|AzPTxxYU6=
UACC-647  M3XIWGZ2dmO2aX;uJGF{e2G7 Mkf1NVDDqM7:TR?= M3q2[FE2KG2rbh?= MnjxSG1UVw>? NWjSRlA2cW6qaXLpeJMhTVKNIIDoc5NxcG:{eXzheIlwdg>? NGPNUVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUewN|AzPSd-MkW3NFMxOjV:L3G+
UACC-647  MnvaSpVv[3Srb36gRZN{[Xl? M1jEVWROW09? MVPs[YFleyC2bzDhJJJqe2ViaX6gZ2FOWCCuZY\lcJMhMEWFNUFCpF3DqDJyLkO5xsDPxE1r M1\SWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{CzNFI2Lz5{NUewN|AzPTxxYU6=
SC MkP2SpVv[3Srb36gRZN{[Xl? M2XmWVAvPSEQvF2= MUm3NkBp NVnGUlVNcW6lcnXhd4V{KGKxdHigT5JwgC1{MDDhcoQhVzFiZYjwdoV{e2mxbjDpckBigG:wLYLlcIF1\WRiU1PzJIJ2fCCxbnz5JGtzd3hvMkFCpC=> M2jnTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{C1PFc1Lz5{NUewOVg4PDxxYU6=
SC MkTjSpVv[3Srb36gRZN{[Xl? MmP2NE42KM7:TR?= Mm\YNlQhcA>? NWm4dYZqdWmvaXPrd{B1cGViZX\m[YN1KG:oIHPBUXAh[W6jbH;nd{BwdiCRMTDhcoQhVUKSIHX4dJJme3Orb36= MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdyNUi3OEc,OjV5MEW4O|Q9N2F-
oocytes M2nBfGZ2dmO2aX;uJGF{e2G7 NXTwd|c4PSEQvF2= NVHLXFc1OjRiaB?= MW\heJRmdnWjdHXzJJJpNWmwc4XsbY4h[WO2aX;uJI9vKG:xY4n0[UBIXkKGIIPp[45q\mmlYX70cJnDqA>? M4XNS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{C3PFU1Lz5{NUewO|g2PDxxYU6=
BeWo MWXGeY5kfGmxbjDBd5NigQ>? NETQ[4QyOOLCit88UeKh NFrUZ|g4OiCq NETJb|FFVVOR NWLUbFB2dWWmaXH0[ZMhSmWZbzDj[YxtKGSrZn\ldoVvfGmjdHnvci=> NV;IU|FCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NVM1OjVpPkK1O|E{PDJ3PD;hQi=>
GH3 MWXGeY5kfGmxbjDBd5NigQ>? M3TiRlHDqM7:TR?= MWS2MYg> M2jvdolv\HWlZYOgVHJNKGGwZDDCcYFtOSxiYoX0JI5wfCCFbH;jb{whdVKQQTDlfJBz\XO|aX;u MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{N{CxPEc,OjV5MkewNVg9N2F-
GH3 NGe1ZWFHfW6ldHnvckBCe3OjeR?= NXvhXYt7OcLizszN NFjZOYU3NWh? MUnheJRmdnWjdHXzJJRp\SClb4Ly[YxifGmxbjDi[ZR4\WWwIGDSUEBidmRiQn3hcFEh\XiycnXzd4lwdg>? Ml3hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MkewNVgoRjJ3N{K3NFE5RC:jPh?=
PC12 MnLaSpVv[3Srb36gRZN{[Xl? NVHiNGdYOjYEoN88US=> NXzC[IsxPDhiaB?= NEmyZVdi[3SrdnH0[ZMh[0GPUB?= M4PERlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[5N|A2Lz5{NUe2PVMxPTxxYU6=
BAECs MnjxSpVv[3Srb36gRZN{[Xl? MWeyOUDPxE1? M4LJUVI1KGh? MVjlcohidmOnczD0bIUh[WO2aY\heIlwdiCxZjDQVGFT|rFiYomgOUDPxE1icnXzeoVz[XS{b3ysJHQ1UFNuIH;yJFQuWEGS MlHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OUi4NlYoRjJ3N{m4PFI3RC:jPh?=
GLUTag  NVTxOFBNTnWwY4Tpc44hSXO|YYm= NWXlOIU5OTEkgJpCuW0> MV20JIg> M{XWRYlv[3KnYYPld{B1cGVicFPSSWIhdGW4ZXzzJJdqfGhidHjlJGlDVVh? M4[0O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEOyOlMyLz5{NUizNlY{OTxxYU6=
GLUTag  NUnaVXdDTnWwY4Tpc44hSXO|YYm= M{fKbVEx6oDLwsXN MY[wM|IwPCCq MVLzeIlufWyjdHXzJGdNWC1zIIPlZ5JmfGmxbjDjc5Rz\WG2ZXSge4l1cCCLQl3Y M4WydVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEOyOlMyLz5{NUizNlY{OTxxYU6=
PBMC MnHaSpVv[3Srb36gRZN{[Xl? MVq1NOKh|ryP M1nLdlI1yqCqwrC= MoDRbY5pcWKrdIOgeIhmKGmwY4LlZZNm\CC|ZXPy[ZRqd25ib3[gWG5HKGmwZIXj[YQh[nlidHjlJGRRTQ>? MnW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6Nk[wO|koRjJ3OE[2NFc6RC:jPh?=
H295R  M4HhXmZ2dmO2aX;uJGF{e2G7 NH25eGoyOMLizszN MkXzOFjDqGh? NXHiW5ZMcW6lcnXhd4V{KHO2ZYLvbYQhdWW2YXLvcIl1\XNiaX6geIhmKGGwZILv[4VvNCCvaX7ldoFtdy1iYX7kJIdtfWOxY3;yeIlkd2mmIIDheIh4[Xm| NHWxcVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi2PVU2Pid-MkW4Olk2PTZ:L3G+
3T3-L1 preadipocytes M3fVXWZ2dmO2aX;uJGF{e2G7 MmrENVAh|ryPwrC= M1rjdlEzKGh? NVG5ZXVkcW6mdXPld{BEWkWEIIDoc5NxcG:{eXzheIlwdiCjbnSgR{9GSlEQsjDlfJBz\XO|aX;u NX;DVFFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NlgxPThpPkK1PVI5ODV6PD;hQi=>
PCCL3 MXvGeY5kfGmxbjDBd5NigQ>? MVWxNEDDvU1? MWmyOEBp MUjlcohidmOnczDEeW95OiCycn;tc5RmeiC2cnHud4NzcXC2aX;uJIFkfGm4aYT5xsDjiIt? NWK2bYZpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlA6PTZpPkK1PVYxQTV4PD;hQi=>
SCG MmTISpVv[3Srb36gRZN{[Xl? MkDqNVAxKM7:TdMg M4H0emROW09? NETHU3lz\WS3Y3XzJJRp\SCneHPpeIFjcWyrdImgc4YhW0OJIH7leZJwdnN? MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4MkGzNkc,OjV7NkKxN|I9N2F-
HEK-293 NWjySlJ6TnWwY4Tpc44hSXO|YYm= M2PBb|M2KM7:TdMg M1TBW2ROW09? MmTqbY5lfWOnczDhJINwdnOyaXP1c5V{KOLCnHnuZYN1cX[jdHnvcwKBpSCxZjD0bIUhU3Z{LkGgZ5VzemWwdB?= NXPD[XlqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlIyOzJpPkK1PVYzOTN{PD;hQi=>
SCG MUnGeY5kfGmxbjDBd5NigQ>? M{nKbVIxKM7:TdMg NXTOSIFsTE2VTx?= NYSxbFROemW4ZYLzbYJtgSC|dYDwdoV{e2W|IFnLWkB4cXSqIHGgTWM2OCCxZjCyOE41KM7:TR?= Mn7KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkKxN|IoRjJ3OU[yNVMzRC:jPh?=
PC-3 M{LXcGNmdGxiVnnhZoltcXS7IFHzd4F6 NHPEVlY1OCEEtV2= MXOyOE81QC95MjDo M{Xnc2ROW09? M3nWXYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTD0bY1mKGSncHXu[IVvfGy7 M4fGZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzPFM3Lz5{NkCyN|g{PjxxYU6=
PC-3 MmjpSpVv[3Srb36gRZN{[Xl? MonBOFAhyrWP MkfCNkBp MUPEUXNQ MVjs[YFleyC2bzDQVFJCKGGldHn2ZZRqd25? NUi0NZFrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlM5OzZpPkK2NFI{QDN4PD;hQi=>
SH-SY5Y NXHGdHpLTnWwY4Tpc44hSXO|YYm= M2PqTlMxKM7:TR?= M{fOPVMxKG2rbh?= NWXHN455TE2VTx?= MlXMd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJIFkfGm4YYTpc44hd2ZiUFvB MkLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkWxN|coRjJ4MEK1NVM4RC:jPh?=
EndoC-βH1 M4PQVWZ2dmO2aX;uJGF{e2G7 MoTrOeKh|ryP MXqxJIg> MnfHcIVi\HNidH:gZUB{fHKxbnegZ2FOWCCrbnPy[YF{\Q>? NF7IN4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyPFU3Oid-Mk[wNlg2PjJ:L3G+
EndoC-βH1 MVjGeY5kfGmxbjDBd5NigQ>? NHrP[2s2yqEQvF2= NHrCd20yKGh? MUXwc5RmdnSrYYTld{BodHWlb4PlMYlv\HWlZXSgbY5{fWyrbjDz[YNz\XSrb36gbY4hfGinIIDy[ZNmdmOnIH;mJIdtfWOxc3W= NVfjVnNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlg2PjJpPkK2NFI5PTZ{PD;hQi=>
RBMECs M4XFNWZ2dmO2aX;uJGF{e2G7 MYK1xsDPxE1? Ml3qNUBp MU\pcohq[mm2czDFUWFRNUmLLXnu[JVk\WRiaX7hZ5RqfmG2aX;uJI9nKFKjcEJCpC=> NYTpNVh1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOFQ3PjNpPkK2NFQ1PjZ|PD;hQi=>
AML-12  NX3GO2pHTnWwY4Tpc44hSXO|YYm= NWewNWZLOjBizszN NYL4OXlZOyCq NXHmbGRocW6mdXPld{B1cGViZHXwbI9{eGixconsZZRqd25ib3[gR3JVSzMEoB?= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2OEm4OUc,OjZyNEi5PFU9N2F-
AML-12  MVfGeY5kfGmxbjDBd5NigQ>? M4PHdVIxKM7:TR?= NXTINm9FOyCq NHzac4R2eC2{ZXf1cIF1\XQEoGDnZ|FiNMLiUHXwZ4stKGGwZNMgS|Zx[8LibWLORUBt\X[nbIO= M{jjdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MES4PVg2Lz5{NkC0PFk5PTxxYU6=
AML-12  NWPiSFVJTnWwY4Tpc44hSXO|YYm= MoPjNlAh|ryP NW\5b4dXOS16IHi= NIrx[2JqdmO{ZXHz[ZMh\2y3Y3;z[UBxem:mdXP0bY9v MnS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNEi5PFUoRjJ4MES4PVg2RC:jPh?=
AML-12  MUnGeY5kfGmxbjDBd5NigQ>? MkfUNlAh|ryP NXH2bGxHOyCq MlnzeZBz\We3bHH0[ZMhfGinIIDoc5NxcG:{eXzheIlwdiCuZY\lcJMh[XRiVHjyMVQyOSCjbnSgV4VzNTR7Mx?= NIn2OYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC0PFk5PSd-Mk[wOFg6QDV:L3G+
Caco-2  MWjGeY5kfGmxbjDBd5NigQ>? MVuwMlEwOS9zMDFOwG0> MVOyOEBp NHHlfnVqdmO{ZXHz[ZMhVVKSMjDwdo91\WmwIHzleoVt MkO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNEmxNFIoRjJ4MES5NVAzRC:jPh?=
Caco-2  MmLESpVv[3Srb36gRZN{[Xl? NEi4U48xNjFxMT:xNEDPxE1? MlTFNlDDqG2rbh?= MlnsbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJIlvfHKjY3XscJVt[XJiY1HNVEBt\X[nbIO= MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2OUGwNkc,OjZyNEmxNFI9N2F-
bovine oocytes M17MPWZ2dmO2aX;uJGF{e2G7 NEfYRZIyODEEoN88US=> NXf2UJZVOTMEoHi= MlLFbY5pcWKrdIOgeIhmKGWoZnXjeEBw\iCQUGDBJIFv\C:xcjDOVHBEKHSxIIP0bY12dGG2ZTDy[ZN2dXC2aX;uJI9nKG2naX;zbZM> MnzXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUG2NVEoRjJ4MEWxOlEyRC:jPh?=
BeWo  MWHGeY5kfGmxbjDBd5NigQ>? Mm\3NlXjiIoQvF2= NHjBZoUzPC92OD:3NkBp MnTzcIVi\HNidH:gZY4hcW6lcnXhd4UhcW5idHjlJIV5eHKnc4Ppc44hd2Zib4To[ZIh\nW|aX;uJI1iemuncoO= MmjWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUO1OFkoRjJ4MEWzOVQ6RC:jPh?=
Spinal cords  MlTqSpVv[3Srb36gRZN{[Xl? NXXpdm93OcLizszN M{fUZlMxKG2rbh?= NXfF[HVle3SrbYXsZZRmeyClQV3QJIxmfmWucx?= NGXWVZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyOlkzPid-Mk[xNlY6OjZ:L3G+
MDCK  M3LpcmZ2dmO2aX;uJGF{e2G7 NI\ofW0yOCEEtV2= MVyyOEBp NXW5U5l7TE2VTx?= M2HoTIlvcGmkaYTzJJRp\SCrbnPy[YF{\WRiZYjwdoV{e2mxbjDv[kBHViClYYXz[YQh[nliVFfGMe6zOQ>? MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJyMkO1Nkc,OjZ{MEKzOVI9N2F-
MDCK  NWq3fmdYTnWwY4Tpc44hSXO|YYm= Mn7hNVAhyrWP NXzSfHVEOjRiaB?= NVTqV4tmTE2VTx?= NEmxO2p2eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCWR1[t{tIyKGGwZDDDWGdHyqB? MoLOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MEKzOVIoRjJ4MkCyN|UzRC:jPh?=
RPMI 8226 NXTMN|JwS2WubDDWbYFjcWyrdImgRZN{[Xl? NXf3S4x6OC1zMECg{txO NYPZRYNmPzMkgJno M{HDVolv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 NEnSSo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkOwOlYzPCd-Mk[zNFY3OjR:L3G+
H929 NUTXPW1xS2WubDDWbYFjcWyrdImgRZN{[Xl? MoHSNE0yODBizszN M{DtfVcz6oDLaB?= M2jkUolv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjNyNk[yOEc,OjZ|ME[2NlQ9N2F-
U266 NWfmfVZXS2WubDDWbYFjcWyrdImgRZN{[Xl? Ml;XNE0yODBizszN MkGzO|LjiImq M3z1UIlv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 NUfzVHlMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zNFY3OjRpPkK2N|A3PjJ2PD;hQi=>
OPM-2 NEO5VYVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUKwMVExOCEQvF2= NYjOOGRRPzMkgJno Mnj3bY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= NX76T|NDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zNFY3OjRpPkK2N|A3PjJ2PD;hQi=>
INA-6 NUO0ZYdwS2WubDDWbYFjcWyrdImgRZN{[Xl? MVWwMVExOCEQvF2= NV7NUIhJPzMkgJno NXj1ZXYzcW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk> MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjNyNk[yOEc,OjZ|ME[2NlQ9N2F-
RBMECs  NESzfYJHfW6ldHnvckBCe3OjeR?= NIWyTHo2yqEQvF2= MXmxxsBp NVvvboxi[myxY3vzJJRp\SCUYXOxJIlv[WO2aY\heIlwdiCrbnT1Z4VlKGK7IFXNRXAuUUl? Mmq3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|NUiwN|koRjJ4M{W4NFM6RC:jPh?=
Mo-DCs MXPGeY5kfGmxbjDBd5NigQ>? MWO1NEDPxE1? NEDMN2YzPOLCiXi= NGm0Xohxem:vb4Tld{BKVC1{MzDwdo9lfWO2aX;uJIlvKHSqZTDzeZBmem6jdHHueEBw\iC8eX3vd4FvKHO2aX31cIF1\WRiTX:tSGN{yqB? NYTacVZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0NVI6PDhpPkK2OFEzQTR6PD;hQi=>
HEK293 M1rCV2Z2dmO2aX;uJGF{e2G7 MY[xNEDPxE1? MXi2JIg> Mn;5bY5kemWjc3XzJJBpd3OyaH;yfYxifGmxbjDv[kBwfmW{ZYjwdoV{e2WmIFvMTGw{KGG2IGO0N|M> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR|NUS5PEc,OjZ2M{W0PVg9N2F-
ASK NF3rT2xHfW6ldHnvckBie3OjeR?= NUTGWlBbOSCqch?= NIfhRpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES5OlQyLz5{OES5OlQyRC:jPh?=
Vero E6 NI\lNlRCdnSrdnnyZYwh[XO|YYm= NIrERmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[2N|U{QSd-MUe2OlM2Ozl:L3G+
epithelial cells M{G1XGZ2dmO2aX;uJIF{e2G7 NG[wfoUyKHWP NEPTPFY1NCB4LDDhcoQhQCCmYYnz MnvVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7Nk[3PFkoRjF7OU[2O|g6RC:jPh?=
HepG2 (DPX-2) MYrGeY5kfGmxbjDhd5NigQ>? NFrWWYYzPCCqcoO= NVrMWYZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC5OlYxPDNpPkKwPVY3ODR|PD;hQi=>
HepG2 MoPzSpVv[3Srb36gZZN{[Xl? M2rtW|I1KGi{cx?= MlzuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7Nk[wOFMoRjJyOU[2NFQ{RC:jPh?=
HepG2 (DPX-2) NX3xWIZZTnWwY4Tpc44h[XO|YYm= Ml21NlQhcHK| NX\3ToVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC5OlYxPDNpPkKwPVY3ODR|PD;hQi=>
HEK293T NWCxc|U2TnWwY4Tpc44h[XO|YYm= MVixNEB2VQ>? NYDLXJhVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPFc{OjVpPkK0N|g4OzJ3PD;hQi=>
HEK293 M1;pUGZ2dmO2aX;uJIF{e2G7 NXHpT3p5OTBidV2= NHLqUIIyPiCqcoO= NULjd|Z{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0N|U2OTJpPkK2OFM2PTF{PD;hQi=>
MCF7 MnSxR5l1d3SxeHnjbZR6KGG|c3H5 MlXjOFghcHK| NETGfmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEizPFY6Oid-Mki4N|g3QTJ:L3G+
HEK293 NIT2NI9HfW6ldHnvckBie3OjeR?= NX;aelJYOzBibXnudy=> M4rWTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEC2NVc3Lz5|MECwOlE4PjxxYU6=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
cleaved caspase-3 / caspase-3; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-3

cleaved caspase-9 / caspase-9 ; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-9.

β-catenin; 

PubMed: 30863177     


(A, B) The protein expression of cytoplasmic and nuclear β-catenin in Toledo and NK-92 cells in the presence of 0, 10, 20, or 40 μM forskolin was detected by Western blotting.

c-myc / Cyclin D1; 

PubMed: 30863177     


(C, D) Western blotting analysis of the total protein expression of c-myc and cyclin D1 influenced by 0, 10, 20, or 40 μM of forskolin in Toledo and NK-92 cells (n=3, *P<0.05, forskolin group vs control group).

pS6K1 / S6K1 / pCREB / CREB; 

PubMed: 31112131     


Forskolin inhibits mTORC1 in multiple cell lines. PC3, LNcap/AR, H1299, H1944, MDA-MB-231, MEF, HAP1, COS7, HeLa, MIA Paca-2, and PANC-1 were treated with or without 10 μM forskolin for 1 h and mTORC1 activity, CREB phosphorylation, and loading controls were analyzed.

p-JNK / JNK / P-p38 / p38; 

PubMed: 20070884     


L929 cells were pretreated with forskolin (10 μM) for various times as indicated, followed by stimulation with or without 10 ng/ml TNF-α for 15 min.

30863177 31112131 20070884
Immunofluorescence
5hmC; 

PubMed: 29239726     


Schwann cells were treated with forskolin (10 μM) for 3 hr followed by washout. 5hmC induction was detected at of 0, 3, and 24 hr time points following treatment. Cells continuously treated with forskolin (5, 10 μM) for 24 hr showed comparable 5hmC levels. Scale bar = 20 μm. 

Fe(II); 

PubMed: 29239726     


AMP (100 mM) treatment for 4 hr did not induce labile Fe(II) while AC activators (forskolin (100 mM), bicarbonate (50 mM)) and PDE inhibitors (caffeine (100 mM), IBMX (100 mM)) increased labile Fe(II) detected by Trx-Puro probes.

CYP17A1 / CYP21A2; 

PubMed: 25334044     


H295R cells were treated with 8-Br-cAMP or forskolin for 48 h under growth conditions, and fixed with 4% paraformaldehyde. (A) Immunostaining for CYP17A1. Red staining shows the anti-CYP17A1 antibody and blue staining shows DAPI (cell nuclei). (B) Immunostaining for CYP21A2. Red staining shows the anti-CYP21A2 antibody and blue staining shows DAPI (cell nuclei). Scale bars represent 100 µm.

29239726 25334044
Growth inhibition assay
Cell viability; 

PubMed: 30863177     


(C) MTT assay was conducted to test the cell growth after Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (D) Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50 of forskolin. (F) MTT assay was conducted to test the cell growth after NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (G) NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50of forskolin. 

30863177

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.75 mM)
Water Insoluble
Ethanol ''37 mg/mL ''37

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 410.5
化学式

C22H34O7

CAS No. 66575-29-9
Storage powder
in solvent
別名 Coleonol, Colforsin
Smiles CC(=O)OC1C(C2C(CCC(C2(C3(C1(OC(CC3=O)(C)C=C)C)O)C)O)(C)C)O

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04254705 Not yet recruiting Procedure: Rectal Biopsy Cystic Fibrosis Universitaire Ziekenhuizen Leuven|Vertex Pharmaceuticals Incorporated|KU Leuven|University of Lisbon March 1 2020 Not Applicable
NCT02807415 Completed Drug: Lumacaftor plus Ivacaftor Cystic Fibrosis Hannover Medical School|Heidelberg University|University of Giessen June 1 2016 --
NCT02586883 Completed Other: bronchial ddp test Idiopathic Dilation of the Bronchi Assistance Publique - Hôpitaux de Paris March 29 2016 Not Applicable
NCT03652090 Completed Procedure: cell sampling Cystic Fibrosis Institut National de la Santé Et de la Recherche Médicale France|ABCF2 September 1 2010 --

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

cAMPシグナル伝達経路

Tags: Colforsin (Forskolin, HL 362)を買う | Colforsin (Forskolin, HL 362) ic50 | Colforsin (Forskolin, HL 362)供給者 | Colforsin (Forskolin, HL 362)を購入する | Colforsin (Forskolin, HL 362)費用 | Colforsin (Forskolin, HL 362)生産者 | オーダーColforsin (Forskolin, HL 362) | Colforsin (Forskolin, HL 362)化学構造 | Colforsin (Forskolin, HL 362)分子量 | Colforsin (Forskolin, HL 362)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID